产品信息
抗原名称
Bcl2-BH4
商品描述
BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
分子量
423.5
纯度
>98%
可溶性
DMSO ：84 mg/mL (198.34 mM)
Ethanol ：5 mg/mL (11.8 mM)
Ethanol ：5 mg/mL (11.8 mM)
外观
Powder
In vitro(体外研究)
BDA-366 induces robust apoptosis in MM(Multiple myeloma) cell lines and primary MM cells by inducing BCL2 conformational change. BDA-366 induces a conformational change in the BCL2 molecule that converts it to a death protein, and inhibits lung cancer growth in vitro and in vivo. BDA-366 did not bind to other Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1, indicating the specificity of its Bcl2 binding. BDA-366 induces apoptotic cell death in a Bax-dependent manner and induces calcium (Ca2+) release via inhibition of Bcl2/IP3R interaction.
In vivo(体内研究)
Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγ null mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Also, BDA-366 suppresses lung cancer growth via induction of apoptosis in animal models. The BH4 antagonist BDA-366 exhibits potent efficacy against human lung cancer in vivo without platelet reduction.
背景
别名
BDA-366,BDA 366,BDA366
分子式
C24H29N3O4
CAS号
1909226-00-1；1821496-27-8
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
参考图片
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.iamyjet.com/article/22160.html